Aclarion, Inc. has released a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon and Lead Clinician at The London Spine Clinic, discussing his experience using the Nociscan diagnostic platform in clinical practice. The video is available here.
Nociscan is a non-invasive solution that leverages magnetic resonance spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain in the lumbar spine. The technology helps physicians differentiate between painful and non-painful discs, providing objective data to complement traditional imaging methods. Mr. Sutcliffe noted that this additional insight can inform clinical decisions and improve confidence when evaluating patients with chronic low back pain.
To date, nearly 100 Nociscans have been conducted at The London Clinic, reflecting increasing utilization and integration into routine clinical practice. Brent Ness, Chief Executive Officer of Aclarion, stated that approaching 100 scans at a leading international center like The London Clinic is an important indicator of growing adoption. This reinforces the potential for Nociscan to become a valuable tool in evaluating chronic low back pain, a condition affecting approximately 266 million people worldwide.
Clinical data has demonstrated that when used alongside other diagnostic tools, Nociscan can contribute to surgical success rates of up to 97% when all Nociscan-positive discs are treated. The technology represents a commercial-stage healthcare application of biomarkers and augmented intelligence algorithms to address a significant global healthcare challenge.
For more information on Nociscan or to find a Nociscan center, interested parties can view the site map here. Additional news and updates relating to Aclarion are available in the company's newsroom.
